Sisunatovir receives Fast Track Designation in US for serious Respiratory Syncytial Virus (RSV) infection

Sisunatovir is an orally administered fusion inhibitor designed to block RSV replication by inhibiting RSV F-mediated fusion of RSV with the host cell. Regulatory review status in the EU is unknown.

Biospace Inc.